Gastrointestinal Special Issue

Genomic testing of gastrointestinal tumors can be essential to proper treatment.

With immunotherapy continuing to command headlines in the world of oncology, it’s no surprise that patients with a variety of cancers wonder whether the strategy might help them address and overcome their illnesses.

It's amazing what a new year can bring.

After 10 years without a new drug for liver cancer, two approvals and a promising pipeline are changing the landscape.

Every survivor of a gastrointestinal cancer has unique follow-up needs. A ‘road map’ for this process can help.

Progress in cholangiocarcinoma treatment was long stalled, but now scientists are identifying genetic drivers likely to respond to novel drugs.

Funded posthumously by a "Jeopardy!" winner, an immunotherapy research project is under way.

A leader of the Pancreatic Cancer Action Network, which aims to double survival rates by 2020, outlines treatment strategies that could lead to success.

“Disease control is key in our patients with locally advanced disease, as it may lead to opportunities for additional treatment interventions, including radiotherapy, or even, in some favorable cases, surgical resection,” said lead study author Pascal Hammel, M.D., Ph.D.

Treatment with the PD-1 inhibitor Keytruda (pembrolizuumab) elicited promising progression-free survival (PFS) and overall survival (OS) results in patients with advanced hepatocellular carcinoma (HCC) who received previous treatment with Nexavar (sorafenib), according to phase 2 findings.

“Patients with advanced hepatocellular carcinoma often have a poor prognosis and limited treatment options following prior systemic therapy,” lead investigator Ghassan K. Abou-Alfa, M.D.

Immunotherapy may play a growing role in treating gastrointestinal cancers categorized as MSI-high.

Laparoscopy proves safer than open surgery and costs less than robotic resection for colorectal cancer.